Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 5/20 | 0.33 |
| ▸ | UTS2R | Q9UKP6 | 2/20 | 0.32 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4439855 | 0.89 | DRD2 (0.34) | DRD2UTS2R | |
| SCHEMBL4430407 | 0.85 | UTS2R (0.45) | DRD2UTS2R | |
| SCHEMBL4428009 | 0.85 | UTS2R (0.45) | DRD2UTS2R | |
| SCHEMBL4884060 | 0.85 | UTS2R (0.46) | DRD2UTS2R | |
| SCHEMBL4432485 | 0.75 | UTS2R (0.56) | DRD2UTS2R | |
| SCHEMBL4431597 | 0.75 | UTS2R (0.58) | UTS2R | |
| SCHEMBL4437091 | 0.74 | UTS2R (0.59) | UTS2R | |
| SCHEMBL4426624 | 0.74 | UTS2R (0.44) | UTS2R | |
| SCHEMBL4433536 | 0.73 | UTS2R (0.45) | UTS2R | |
| SCHEMBL4431353 | 0.71 | MAPT (0.40) | DRD2UTS2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8759342-B2 | Benzo[1,4]oxazin-3-one, benzo[1,4]thiazin-3-one and quinolin-2-one urotensin II receptor antagonists | JANSSEN PHARMACEUTICA NV (BE) | 2014-06-24 | — | — | US | claimed |
| US-20080039454-A1 | Urotensin II receptor antagonists | JANSSEN PHARMACEUTICA, N.V. (BE) | 2008-02-14 | — | — | US | claimed |
| US-8759342-B2 | Benzo[1,4]oxazin-3-one, benzo[1,4]thiazin-3-one and quinolin-2-one urotensin II receptor antagonists | JANSSEN PHARMACEUTICA NV (BE) | 2014-06-24 | — | — | US | disclosed |
| EP-2049120-A1 | UROTENSIN II RECEPTOR ANTAGONISTS | Janssen Pharmaceutica, N.V. (BE) | 2009-04-22 | — | — | EP | disclosed |
| US-20080039454-A1 | Urotensin II receptor antagonists | JANSSEN PHARMACEUTICA, N.V. (BE) | 2008-02-14 | — | — | US | disclosed |
| WO-2008016534-A1 | UROTENSIN II RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2008-02-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080039454-A1 | Urotensin II receptor antagonists | UTS2R, PLAUR, NTSR2 | DRD2 731/4885UTS2R 1/4885ADORA3 376/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.